For a short-term investment strategy, the company has poor fundamentals.
The current area is a good opportunity for investors interested in buying the stock in a mid or long-term perspective. Indeed, the share is moving closer to its lower bound at USD 37.13 USD in weekly data.
Graphically speaking, the timing seems perfect for purchasing the stock close to the USD 36.95 support.
Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
Analysts covering this company mostly recommend stock overweighting or purchase.
The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
Engages in the discovery, development, manufacture and sale of health care productsAbbott Laboratories engages in the discovery, development, manufacture and sale of a broad and diversified line of health care products.It operates through four reportable segments: Established Pharmaceutical...